Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright

Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Belite Bio in a report issued on Wednesday, May 21st. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.49) for the quarter. HC Wainwright currently has a "Buy" rating and a $100.00 target price on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio's Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.49) EPS and Q4 2026 earnings at ($0.49) EPS.

Belite Bio (NASDAQ:BLTE - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02).

A number of other analysts have also recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Belite Bio in a research note on Thursday, May 15th. Wall Street Zen lowered shares of Belite Bio from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Benchmark reissued a "buy" rating and issued a $80.00 price target on shares of Belite Bio in a report on Wednesday, March 26th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Belite Bio has an average rating of "Moderate Buy" and an average target price of $96.67.

Belite Bio Stock Performance

Belite Bio stock traded up $0.13 during trading hours on Friday, reaching $61.76. 10,991 shares of the company's stock traded hands, compared to its average volume of 49,529. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -55.63 and a beta of -1.48. Belite Bio has a fifty-two week low of $43.70 and a fifty-two week high of $86.53. The firm's 50 day moving average is $61.16 and its 200-day moving average is $62.53.

Hedge Funds Weigh In On Belite Bio

Several hedge funds have recently made changes to their positions in BLTE. Alyeska Investment Group L.P. acquired a new position in Belite Bio during the first quarter worth $5,538,000. GAMMA Investing LLC lifted its position in Belite Bio by 43.3% during the 1st quarter. GAMMA Investing LLC now owns 1,849 shares of the company's stock worth $122,000 after buying an additional 559 shares in the last quarter. Bank of America Corp DE lifted its position in Belite Bio by 36.4% during the 4th quarter. Bank of America Corp DE now owns 18,342 shares of the company's stock worth $1,157,000 after buying an additional 4,891 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of Belite Bio during the 4th quarter worth about $155,000. Finally, XTX Topco Ltd grew its holdings in shares of Belite Bio by 30.9% in the 4th quarter. XTX Topco Ltd now owns 7,062 shares of the company's stock valued at $446,000 after acquiring an additional 1,668 shares in the last quarter. 0.53% of the stock is owned by institutional investors.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.